Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to increase availability of Givinostat for children.

The Department understands the impact that Duchenne muscular dystrophy has on those living with it and their families, and the urgent need for new treatment options. The National Institute for Health and Care Excellence (NICE) makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS independently based on an assessment of their costs and benefits. The NHS in England is legally required to fund medicines recommended by the NICE, normally within three months of the publication of final guidance. The NICE is currently evaluating givinostat for the treatment of Duchenne muscular dystrophy and its independent Appraisal Committee will meet to consider the evidence in July 2025.